Table 2. Comparison of clinical data of SARS-CoV-2-infected patients in each group.
F: ANOVA; χ²: chi-square test; -: Fisher exact; P < 0.05 indicates statistical significance.
≧1: patient's lymphocyte count on admission ≧1 (10^9/L); <1: patient's lymphocyte count on admission <1 (10^9/L).
| Variables | Total (n = 338) | Group | Statistic | P | |||
| Unvaccinated | Vaccinated | ||||||
| ≧1 | <1 | ≧1 | <1 | ||||
| A (n = 51) | B (n = 66) | C (n = 108) | D (n = 113) | ||||
| Length of hospitalization (days), mean ± SD | 8.62 ± 6.70 | 8.35 ± 5.16 | 7.86 ± 5.52 | 7.78 ± 5.60 | 9.97 ± 8.53 | F = 2.443 | 0.064 |
| Type of pneumonia, n (%) | χ² = 5.867 | 0.119 | |||||
| Non-critical | 252 (74.6) | 35 (68.6) | 44 (66.7) | 88 (81.5) | 85 (75.2) | ||
| Critical | 86 (25.4) | 16 (31.4) | 22 (33.3) | 20 (18.5) | 28 (24.8) | ||
| Secondary infection, n (%) | - | 0.184 | |||||
| Yes | 23 (6.8) | 6 (11.76) | 3 (4.55) | 4 (3.70) | 10 (8.85) | ||
| No | 315 (93.2) | 45 (88.24) | 63 (95.45) | 104 (96.30) | 103 (91.15) | ||
| The proportion of infiltrating lung shadows in COVID-19, n (%) | - | 0.011 | |||||
| 0 | 64 (18.93) | 6 (11.76) | 12 (18.18) | 27 (25.00) | 19 (16.81) | ||
| <30% | 196 (57.99) | 31 (60.78) | 34 (51.52) | 61 (56.48) | 70 (61.95) | ||
| 30-50% | 13 (3.85) | 1 (1.96) | 9 (13.64) | 2 (1.85) | 1 (0.88) | ||
| >50% | 35 (10.36) | 10 (19.61) | 5 (7.58) | 9 (8.33) | 11 (9.73) | ||
| Other | 30 (8.88) | 3 (5.88) | 6 (9.09) | 9 (8.33) | 12 (10.62) | ||